Barba-Vidal Emili, Castillejos Lorena, López-Colom Paola, Rivero Urgell Montserrat, Moreno Muñoz José A, Martín-Orúe Susana M
Animal Nutrition and Welfare Service, Departament de Ciència Animal i dels Aliments, Universitat Autònoma de BarcelonaBellaterra, Spain.
Laboratorios Ordesa S. L., Investigación BásicaBarcelona, Spain.
Front Microbiol. 2017 Apr 11;8:533. doi: 10.3389/fmicb.2017.00533. eCollection 2017.
Probiotics have been demonstrated to be useful to enhance gut health and prevent gastrointestinal infections. The objective of this study is to demonstrate the potential of the probiotic strain subsp. CECT 7210 ( IM1) to prevent and fight intestinal disease by using a Typhimurium (Trial 1) or an enterotoxigenic K88 (Trial 2) oral challenge in a weaning piglet model. Seventy-two piglets were used in each trial. After an adaptation period, animals were orally challenged. One animal per pen was euthanized at Days 4 and 8/9 (Trial 1/Trial 2) post-inoculation (PI). Animal performance, clinical signs, pathogen excretion, fermentation, immune response, and intestinal morphology were evaluated. In Trial 1, most parameters responded to the challenge, whereas, in Trial 2, effects were much milder. Consistent effects of the probiotic were detected in both experiments: Reduction of pathogen excretion ( = 0.043 on Day 3 PI, Trial 1) or ileal colonization (33% reduction of animals with countable coliforms; = 0.077, Trial 2); increases in intraepithelial lymphocytes ( = 0.002 on Day 8 PI in Trial 1, = 0.091 on Day 4 PI in Trial 2), and improvement of the fermentation profile by increasing butyric acid in non-challenged animals [ challenge × probiotic (interaction) = 0.092 in Trial 1 and = 0.056 in Trial 2] concomitant with an enhancement of the villus:crypt ratio on Day 8/9 PI ( interaction = 0.091 for Trial 1 and = 0.006 for Trial 2). Challenged animals treated with the probiotic showed reduced feed intakes ( interaction = 0.019 in Trial 1 and = 0.020 in Trial 2) and had lower short-chain fatty acid concentrations in the colon ( interaction = 0.008 in Trial 1 and = 0.082 in Trial 2). In conclusion, this probiotic demonstrated potential to reduce the intestinal colonization by pathogens and to stimulate local immune response. However, effects on feed intake, microbial fermentation, and intestinal architecture showed a differential pattern between challenged and non-challenged animals. Effects of the probiotic intervention were dependent on the structure of the ecosystem in which it was applied.
益生菌已被证明有助于增强肠道健康并预防胃肠道感染。本研究的目的是通过在断奶仔猪模型中使用鼠伤寒沙门氏菌(试验1)或产肠毒素大肠杆菌K88(试验2)进行口服攻毒,来证明益生菌菌株亚种CECT 7210(IM1)预防和对抗肠道疾病的潜力。每个试验使用72头仔猪。经过适应期后,对动物进行口服攻毒。在接种后第4天和第8/9天(试验1/试验2),每栏处死1只动物。评估动物的生长性能、临床症状、病原体排泄、发酵情况、免疫反应和肠道形态。在试验1中,大多数参数对攻毒有反应,而在试验2中,影响则要温和得多。在两个实验中均检测到益生菌的一致效果:病原体排泄减少(试验1中接种后第3天P<0.043)或回肠定植减少(可计数大肠菌群的动物减少33%;试验2中P<0.077);上皮内淋巴细胞增加(试验1中接种后第8天P<0.002,试验2中接种后第4天P<0.091),并且在未攻毒的动物中通过增加丁酸改善发酵谱[试验1中攻毒×益生菌(交互作用)P<0.092,试验2中P<0.056],同时在接种后第8/9天绒毛高度与隐窝深度比值增加(试验1中交互作用P<0.091,试验2中P<0.006)。用益生菌处理的攻毒动物采食量降低(试验1中交互作用P<0.019,试验2中P<0.020),结肠中短链脂肪酸浓度较低(试验1中交互作用P<0.008,试验2中P<0.082)。总之,这种益生菌显示出减少病原体在肠道定植并刺激局部免疫反应的潜力。然而,对采食量、微生物发酵和肠道结构的影响在攻毒和未攻毒动物之间表现出不同的模式。益生菌干预的效果取决于其应用的生态系统结构。